Research Article

CACNA1B (Cav2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer

Table 1

Correlation of CACNA1B (2.2) expression in tumor tissues with clinicopathologic characteristics in non-small cell lung cancer (NSCLC) patients.

Clinicopathologic characteristicsCACNA1B (2.2)
Low or no expression High expressionPearson χ2

Total14058 (41.43)82 (58.57)29.594
Gender
 Male69 22 (31.88)47 (68.12)5.1080.018
 Female71 36 (50.70)35 (49.30)
Age at diagnosis (years)
 ≤6066 26 (39.39)40 (60.61)2.0630.103
 >607432 (43.24)42 (56.76)
Tumor size (cm)
 ≤375 40 (53.33) 35 (46.67)9.4350.002
 >36518 (27.69) 47 (72.31)
Histopathology grading
 Adenocarcinoma9245 (48.91)47 (51.09)9.2220.010
 Squamous cell carcinoma3011 (36.67)19 (63.33)
 Others182 (11.11)16 (88.89)
Lymph node metastasis
 No regional lymph node metastasis9849 (50.00)49 (50.00)
 Metastasis in ipsilateral peribronchial lymph nodes226 (27.27)16 (72.73)10.5410.005
 Metastasis in mediastinal lymph nodes203 (15.00)17 (85.00)
Smoking
 Smoking204 (20.00)16 (80.00)4.4150.029
 No smoking12054 (45.00)66 (55.00)
Stage grouping with TNM
 Stage I218 (38.10)13 (61.90)1.7300.421
 Stage II4616 (34.78)30 (65.22)
 Stage III7334 (46.58)39 (53.42)

; a, others, adenosquamous carcinoma.